This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol Myers Squibb (BMY) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Bristol Myers Squibb (BMY) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $61.48 in the latest trading session, marking a -1.09% move from the prior day.
Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
by Zacks Equity Research
Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.
Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.35, marking a -0.27% move from the previous day.
The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed the most recent trading day at $62.35, moving +0.1% from the previous trading session.
Top Research Reports for salesforce, Intuit & Bristol-Myers
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, inc. (CRM), Intuit Inc. (INTU), and Bristol-Myers Squibb Company (BMY).
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $61.45 in the latest trading session, marking a -0.44% move from the prior day.
Bristol Myers' (BMY) Orencia Gets FDA Nod for New Indication
by Zacks Equity Research
The FDA approves Bristol Myers' (BMY) Orencia in combination with a calcineurin inhibitor and methotrexate to prevent acute graft versus host disease. This is the fourth FDA-approved indication for the drug.
Exelixis (EXEL) Initiates Study on XL092 in Advanced Solid Tumors
by Zacks Equity Research
Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $60.61 in the latest trading session, marking a +1.85% move from the prior day.
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More
by Zacks Equity Research
Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $59.51, marking a +0.78% move from the previous day.
Bristol-Myers (BMY) Up on Dividend Hike, Share Repurchase
by Zacks Equity Research
Bristol-Myers (BMY) increases its quarterly dividend and announces a share repurchase program. Consequently, the stock gains.
Sanofi (SNY) Multiple Myeloma Phase III Study Meets Goal
by Zacks Equity Research
Sanofi's (SNY) phase III study on Sarclisa is the first to meet the primary endpoint of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More
by Ekta Bagri
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
Bristol Myers (BMY) sBLA for Reblozyl Gets Priority Review
by Zacks Equity Research
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.
Aurinia (AUPH) Stock Up on Potential Acquisition Rumors
by Zacks Equity Research
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Amgen (AMGN) Kyprolis Gets FDA Nod for Use With Darzalex Faspro
by Zacks Equity Research
Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.
Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through
by Zacks Equity Research
Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.
Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition
by Zacks Equity Research
Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.